Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419 |
| |
Authors: | Yamanaka Toshio Ohkubo Mitsuru Kuroda Satoru Nakamura Hideko Takahashi Fumie Aoki Toshiaki Mihara Kayoko Seki Jiro Kato Masayuki |
| |
Institution: | Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, 2-1-6 Kashima, Yodogawa-Ku, Osaka 532-8514, Japan. toshio.yamanaka@jp.astellas.com |
| |
Abstract: | The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the beta-turn structure of RGD peptide sequences in the alpha chain of fibrinogen, which binds the glycoprotein IIb/IIIa (GPIIb/IIIa) on the surface of platelets to induce platelet aggregation, the prototype 2 was designed. After further substituent effects were investigated at the alpha-position of the carboxylic acid in 2, we enhanced platelet aggregation inhibition, and discovered the useful feature of reduced prolongation of bleeding time. Finally, the potent platelet aggregation inhibitor FK419 (3) could be discovered. FK419 shows a safe feature of reduced prolongation of bleeding time, as well as potent inhibition of platelet aggregation. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|